Sustained remission after combination therapy with rituximab and etanercept in two patients with rheumatoid arthritis after TNF failure: Case report

Open Rheumatology Journal

Volumn 3, Issue , 2009, Pages 9-13

  Feuchtenberger, Martin ^a   Kneitz, Christian ^a   Roll, Petra ^a   Kleinert, Stefan ^a   Tony, Hans Peter ^a  

^a NONE

Author keywords

Etanercept; Rheumatoid arthritis; Rituximab; TNF failure

Indexed keywords

ANTIBIOTIC AGENT; CHLOROQUINE; CLEMASTINE; ETANERCEPT; GOLD; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEFLUNOMIDE; METHOTREXATE; PARACETAMOL; PREDNISOLONE; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADULT; ARTICLE; B LYMPHOCYTE; CASE REPORT; CHRONIC BRONCHITIS; DISEASE ACTIVITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INFECTION; LYMPHOCYTE DEPLETION; PNEUMONIA; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; THROMBOCYTOPENIA;

EID: 77953395369     PISSN: None     EISSN: 18743129     Source Type: Journal    
DOI: 10.2174/1874312900903010009     Document Type: Article

References (12)

1. Paleolog E. The therapeutic potential of TNF-alpha blockade in rheumatoid arthritis. Expert Opin Investig Drugs 2003; 12(7): 1087-95.
2. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54(3): 711-5.
3. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-celltargeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350(25): 2572-81.
4. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54(5): 1390-400.
5. Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006; 8(1): R29.
6. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007; 56(1): 13-20.
7. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353(11): 1114-23.
8. O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334(20): 1287-91.
9. Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50(5): 1412-9.
10. Blank N, Max R, Briem S, Lorenz H. Combination Therapy with Rituximab and Etanercept for patients with rheumatoid arthritis. THU0165 EULAR 2008, Paris.
11. Genovese MC, Breedveld F, Emery P, et al. Safety of Other Biologic Therapies Following Rituximab Treatment in RA Patients. TUE 1671/393, ACR 2008, San Francisco.
12. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006; 54(8): 2377-86.